(Q37180600)

18 August 2017

Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function (English)

1 reference

18 August 2017

3

G Giovannoni

1 reference

18 August 2017

B O Khatri

1

1 reference

18 August 2017

S Man

2

1 reference

18 August 2017

A P Koo

4

1 reference

18 August 2017

J-C Lee

5

1 reference

18 August 2017

B Tucky

6

1 reference

18 August 2017

F Lynn

7

1 reference

18 August 2017

S Jurgensen

8

1 reference

18 August 2017

J Woodworth

9

1 reference

18 August 2017

S Goelz

10

1 reference

18 August 2017

P W Duda

11

1 reference

18 August 2017

M A Panzara

12

1 reference

18 August 2017

R M Ransohoff

13

1 reference

18 August 2017

R J Fox

14

1 reference

18 August 2017

language of work or name

English

0 references

publication date

1 February 2009

1 reference

18 August 2017

8

1 reference

inferred from page(s)

published in

Neurology

1 reference

18 August 2017

72

1 reference

18 August 2017

5

1 reference

18 August 2017

402-409

1 reference

Natalizumab for multiple sclerosis

18 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2677532

Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2677532

Inflammatory cell migration into the central nervous system: a few new twists on an old tale

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2677532

Potential risk of progressive multifocal leukoencephalopathy with natalizumab therapy: possible interventions

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2677532

Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2677532

Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2677532

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2677532

Natalizumab Induction and Maintenance Therapy for Crohn's Disease

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2677532

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2677532

Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2677532

Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2677532

Progressive multifocal leukoencephalopathy in a patient treated with natalizumab

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2677532

Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2677532

Successful outcome of progressive multifocal leukoencephalopathy in a renal transplant patient

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2677532

Progressive multifocal leukoencephalopathy in transplant recipients

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2677532

A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2677532

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2677532

Recent advances in immunological therapy: plasma-exchange and immunosuppression

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2677532

CXCR3 marks CD4+ memory T lymphocytes that are competent to migrate across a human brain microvascular endothelial cell layer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2677532

Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2677532

Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin.

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2677532

A randomized, controlled trial of daclizumab vs anti-thymocyte globulin induction for lung transplantation

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2677532

Determinants of CCL5-driven mononuclear cell migration across the blood-brain barrier. Implications for therapeutically modulating neuroinflammation.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2677532

Immune surveillance in multiple sclerosis patients treated with natalizumab.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2677532

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2677532

The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2677532

A controlled trial of natalizumab for relapsing multiple sclerosis.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2677532

HAART improves prognosis in HIV-associated progressive multifocal leukoencephalopathy.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2677532

PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY AFTER RITUXIMAB IN A CASE OF NON-HODGKIN LYMPHOMA

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2677532

4 December 2018

1 reference

12 December 2020

Progressive multifocal leukoencephalopathy after allogeneic stem cell transplantation and posttransplantation rituximab

1 reference

12 December 2020

Vascular access via temporary radial artery catheterization for therapeutic plasma exchange

1 reference

12 December 2020

Controlled trial of plasma exchange in acute inflammatory polyradiculoneuropathy

1 reference

12 December 2020

Chronic progressive multiple sclerosis: double-blind controlled study of plasmapheresis in patients taking immunosuppressive drugs

1 reference

12 December 2020

Plasmapheresis in myasthenia gravis. A comparative study of daily versus alternately daily schedule

1 reference

12 December 2020

Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis

1 reference

12 December 2020

10.1212/01.WNL.0000341766.59028.9D

Identifiers

DOI

1 reference

18 August 2017

1 reference

18 August 2017

1 reference